B
CYTK icon

Bailard’s Cytokinetics CYTK Stock Holding History

Bailard’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,425
Closed -$218K – 763
2025
Q4 		$218K Buy
+3,425
New +$213K ﹤0.01% 686

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bailard's CYTK Position: Q1 2026 in Review

Bailard sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 3,425 shares — an estimated $218K sold.

Bailard first reported a position in CYTK in Q4 2025 and held it in 1 quarter. The position peaked at $218K in Q4 2025. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Bailard reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Bailard sold 3,425 Cytokinetics shares in Q1 2026, an estimated $218K.
  • Bailard first reported a position in Cytokinetics in Q4 2025 and held it in 1 quarter.
  • Bailard's Cytokinetics position peaked at $218K in Q4 2025.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.